|
CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE HEBDOMADAIRE |
|
|
Référence |
chimiothérapie |
stade |
nb pts |
RO |
p |
SM |
p |
DIR |
|
Sculier, 1993 |
1. ADR-VP16-CPA~ CDDP-VDS~MTX-VCR |
tous |
107 |
69% |
NS |
49s |
NS |
71% |
|
2. ADR-CPA-VP16 |
108 |
61% |
43s |
85% |
||||
|
Souhami, 1994 |
1.CDDP-VP16~Ifo-ADR |
tous |
221 |
82% |
NS |
11m |
NS |
73% |
|
2.CDDP-VP16~VAC |
217 |
81% |
11m |
93% |
||||
|
James, 1996 |
1.CDDP-VP16~VAC |
tous |
78 |
59% |
NS |
6m |
NS |
87% |
|
2.CDDP-VP16~VAC |
89 |
45% |
6m |
90% |
||||
|
Furuse, 1998 |
1.CDDP-VP16~VAC |
ME |
113 |
76% |
NS |
11m |
NS |
82% |
|
2.CODE + G-CSF (CDDP-ADR-VP16-VCR) |
114 |
85% |
12m |
72% |
||||
|
Murray, 1999 |
1. CODE |
ME |
110 |
87% |
S |
0,98 an |
NS |
|
|
2. CAV ~ CDDP-VP16 |
109 |
70% |
0,91 an |
|||||
|
Sekine, 2003 |
CDDP-VP16-Irinotecan |
ME |
||||||
|
1. hebdomadaire |
30 |
80% |
8,9 m |
|||||
|
2. mensuel |
30 |
67% |
12 ,9 m |
Références
(1) Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11(10):1858-1865.
(2) Souhami RL, Rudd R, Ruiz dEM, James L, Gower N, Harper PG et al. Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994; 12(9):1806-1813.
(3) James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. Br J Cancer 1996; 73(12):1563-1568.
(4) Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998; 16(6):2126-2132.
(5) Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17(8):2300-2308.
(6) Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003; 14(5):709-714.